614 related articles for article (PubMed ID: 28529645)
1. Tumor Penetrating Theranostic Nanoparticles for Enhancement of Targeted and Image-guided Drug Delivery into Peritoneal Tumors following Intraperitoneal Delivery.
Gao N; Bozeman EN; Qian W; Wang L; Chen H; Lipowska M; Staley CA; Wang YA; Mao H; Yang L
Theranostics; 2017; 7(6):1689-1704. PubMed ID: 28529645
[TBL] [Abstract][Full Text] [Related]
2. IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer.
Zhou H; Qian W; Uckun FM; Wang L; Wang YA; Chen H; Kooby D; Yu Q; Lipowska M; Staley CA; Mao H; Yang L
ACS Nano; 2015 Aug; 9(8):7976-91. PubMed ID: 26242412
[TBL] [Abstract][Full Text] [Related]
3. Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles.
Satpathy M; Wang L; Zielinski RJ; Qian W; Wang YA; Mohs AM; Kairdolf BA; Ji X; Capala J; Lipowska M; Nie S; Mao H; Yang L
Theranostics; 2019; 9(3):778-795. PubMed ID: 30809308
[TBL] [Abstract][Full Text] [Related]
4. uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection.
Yang L; Sajja HK; Cao Z; Qian W; Bender L; Marcus AI; Lipowska M; Wood WC; Wang YA
Theranostics; 2013; 4(1):106-18. PubMed ID: 24396518
[TBL] [Abstract][Full Text] [Related]
5. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer.
Lee GY; Qian WP; Wang L; Wang YA; Staley CA; Satpathy M; Nie S; Mao H; Yang L
ACS Nano; 2013 Mar; 7(3):2078-89. PubMed ID: 23402593
[TBL] [Abstract][Full Text] [Related]
6. Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer.
Miller-Kleinhenz J; Guo X; Qian W; Zhou H; Bozeman EN; Zhu L; Ji X; Wang YA; Styblo T; O'Regan R; Mao H; Yang L
Biomaterials; 2018 Jan; 152():47-62. PubMed ID: 29107218
[TBL] [Abstract][Full Text] [Related]
7. Theranostic pH-sensitive nanoparticles for highly efficient targeted delivery of doxorubicin for breast tumor treatment.
Pan C; Liu Y; Zhou M; Wang W; Shi M; Xing M; Liao W
Int J Nanomedicine; 2018; 13():1119-1137. PubMed ID: 29520140
[TBL] [Abstract][Full Text] [Related]
8. Functionalized milk-protein-coated magnetic nanoparticles for MRI-monitored targeted therapy of pancreatic cancer.
Huang J; Qian W; Wang L; Wu H; Zhou H; Wang AY; Chen H; Yang L; Mao H
Int J Nanomedicine; 2016; 11():3087-99. PubMed ID: 27462153
[TBL] [Abstract][Full Text] [Related]
9. Theranostic nanoparticles carrying doxorubicin attenuate targeting ligand specific antibody responses following systemic delivery.
Yang E; Qian W; Cao Z; Wang L; Bozeman EN; Ward C; Yang B; Selvaraj P; Lipowska M; Wang YA; Mao H; Yang L
Theranostics; 2015; 5(1):43-61. PubMed ID: 25553097
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of a urokinase plasminogen activator receptor-targeted nanoprobe in rhesus monkeys.
Chen Y; Gong L; Gao N; Liao J; Sun J; Wang Y; Wang L; Zhu P; Fan Q; Wang YA; Zeng W; Mao H; Yang L; Gao F
Int J Nanomedicine; 2015; 10():6689-98. PubMed ID: 26604745
[TBL] [Abstract][Full Text] [Related]
11. DOT corrected fluorescence molecular tomography using targeted contrast agents for small animal tumor imaging.
Tan Y; Cao Z; Sajja HK; Lipowska M; Wang YA; Yang L; Jiang H
J Xray Sci Technol; 2013; 21(1):43-52. PubMed ID: 23507851
[TBL] [Abstract][Full Text] [Related]
12. Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles.
Yang L; Mao H; Cao Z; Wang YA; Peng X; Wang X; Sajja HK; Wang L; Duan H; Ni C; Staley CA; Wood WC; Gao X; Nie S
Gastroenterology; 2009 May; 136(5):1514-25.e2. PubMed ID: 19208341
[TBL] [Abstract][Full Text] [Related]
13. IGF-1 receptor targeted nanoparticles for image-guided therapy of stroma-rich and drug resistant human cancer.
Zhou H; Qian W; Uckun FM; Zhou Z; Wang L; Wang A; Mao H; Yang L
Proc SPIE Int Soc Opt Eng; 2016 Apr; 9836():. PubMed ID: 27313332
[TBL] [Abstract][Full Text] [Related]
14. EGFR Targeted Theranostic Nanoemulsion for Image-Guided Ovarian Cancer Therapy.
Ganta S; Singh A; Kulkarni P; Keeler AW; Piroyan A; Sawant RR; Patel NR; Davis B; Ferris C; O'Neal S; Zamboni W; Amiji MM; Coleman TP
Pharm Res; 2015 Aug; 32(8):2753-63. PubMed ID: 25732960
[TBL] [Abstract][Full Text] [Related]
15. Molecular photoacoustic tomography of breast cancer using receptor targeted magnetic iron oxide nanoparticles as contrast agents.
Xi L; Grobmyer SR; Zhou G; Qian W; Yang L; Jiang H
J Biophotonics; 2014 Jun; 7(6):401-9. PubMed ID: 23125139
[TBL] [Abstract][Full Text] [Related]
16. Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy.
Abdalla MO; Karna P; Sajja HK; Mao H; Yates C; Turner T; Aneja R
J Control Release; 2011 Feb; 149(3):314-22. PubMed ID: 21047537
[TBL] [Abstract][Full Text] [Related]
17. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
[TBL] [Abstract][Full Text] [Related]
18. Probing and Enhancing Ligand-Mediated Active Targeting of Tumors Using Sub-5 nm Ultrafine Iron Oxide Nanoparticles.
Xu Y; Wu H; Huang J; Qian W; Martinson DE; Ji B; Li Y; Wang YA; Yang L; Mao H
Theranostics; 2020; 10(6):2479-2494. PubMed ID: 32194814
[No Abstract] [Full Text] [Related]
19. Real-time near-infrared bioimaging of a receptor-targeted cytotoxic dendritic theranostic agent.
Wu J; Zhou Y; Li S; Qu D; Zhu WH; Tian H
Biomaterials; 2017 Mar; 120():1-10. PubMed ID: 28011190
[TBL] [Abstract][Full Text] [Related]
20. Curcumin-lipoic acid conjugate as a promising anticancer agent on the surface of gold‑iron oxide nanocomposites: A pH-sensitive targeted drug delivery system for brain cancer theranostics.
Ghorbani M; Bigdeli B; Jalili-Baleh L; Baharifar H; Akrami M; Dehghani S; Goliaei B; Amani A; Lotfabadi A; Rashedi H; Haririan I; Alam NR; Hamedani MP; Khoobi M
Eur J Pharm Sci; 2018 Mar; 114():175-188. PubMed ID: 29248558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
